Tα1's primary research application is immune modulation — specifically, the promotion of T-cell differentiation and function. Research has shown that Tα1 promotes the maturation of T-cell progenitors into functional CD4+ and CD8+ T-cells, enhances natural killer cell activity, and increases the production of cytokines including IL-2, IFN-alpha, and IFN-gamma.1
IMMUNE
Thymosin Alpha 1
$59.99
Thymosin Alpha 1 is a synthetic 28-amino-acid peptide fragment derived from pro-thymosin α, classified as an immunomodulatory research peptide. It is widely used in laboratory settings to investigate cellular regulation, biochemical signaling pathways, and interactions with immune-related molecular targets. Intended strictly for controlled research applications only.
QuantityStandard research vial
PuritySee COA
Free shipping on orders over $200
Download Certificate of AnalysisAbout This Compound
Product Overview
Thymosin Alpha 1 (Tα1) is a 28-amino-acid peptide originally isolated from the thymus gland — the organ responsible for T-cell maturation and immune system development. It was first identified by Dr. Allan Goldstein at the George Washington University in the 1970s and has since become one of the most extensively studied immune-modulating peptides in the scientific literature.
Tα1 is notable among OSYRIS products because it has an established clinical history outside the United States. A synthetic version (thymalfasin, marketed as Zadaxin) has been approved in over 35 countries for specific immune-related indications, though it has not received FDA approval in the United States. This clinical history provides a more robust evidence base than most research peptides, with data from multiple clinical trials.
Research Applications
Mechanism and Experimental Context
Tα1 has been studied for its effects on dendritic cells — the immune system's antigen-presenting cells that initiate adaptive immune responses. Research demonstrated that Tα1 treatment enhanced dendritic cell maturation, antigen uptake, and cross-presentation to T-cells, potentially improving the efficiency of immune surveillance.2
A significant body of Tα1 research involves viral immunity models. Clinical trials (primarily outside the US) have investigated Tα1 in the context of hepatitis B and hepatitis C, where it was studied as an adjunct to standard antiviral therapy. These trials provided data on Tα1's ability to enhance immune responses against chronic viral infections.3
Tα1 is studied in the context of immune aging (immunosenescence) — the gradual deterioration of immune function that occurs with age. The thymus itself undergoes significant involution (shrinkage) with age, and thymic peptide decline has been associated with reduced T-cell diversity and impaired immune surveillance in aging populations.4
Explore Related Compounds
Keep the Research Trail Moving
Referenced Studies
Source Literature
[1]
Goldstein AL, et al. "Thymosin alpha 1: from bench to bedside." Annals of the New York Academy of Sciences, 2007. PubMed: PMID 17413005
[2]
Romani L, et al. "Thymosin alpha 1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance." Blood, 2006. PubMed: PMID 16352815
[3]
Garaci E, et al. "Thymosin alpha 1 in the treatment of viral diseases of the liver." International Immunopharmacology, 2003.
[4]
Pica F, et al. "Thymosin alpha 1 and immunosenescence." Vitamins and Hormones, 2016.
Certificate of Analysis
Batch Documentation
Current published batch documentation is surfaced on-page whenever the provider exposes a public COA asset.
Frequently Asked Questions
Questions About Thymosin Alpha 1
A 28-amino-acid peptide originally isolated from the thymus gland. It promotes T-cell maturation, enhances NK cell activity, and modulates cytokine production. It has been approved in 35+ countries (not the US) for clinical use.
Not in the United States. A synthetic version (thymalfasin/Zadaxin) has been approved in over 35 countries for specific indications. OSYRIS Thymosin Alpha 1 is sold as a research compound for laboratory research only.
An organ located behind the breastbone that is critical for T-cell development and immune system maturation. The thymus is most active during childhood and progressively shrinks (involutes) with age.
The gradual decline in immune function that occurs with aging. It includes reduced T-cell diversity, impaired immune surveillance, and decreased vaccine responsiveness. Thymic peptides like Tα1 are studied as potential modulators of this process.
Lyophilized at 2-8°C or -20°C. Protect from light and moisture.
Independently tested via HPLC and LC-MS. COA downloadable on this page.
No. They are different peptides from different thymic fractions. Thymosin Alpha 1 (28 amino acids) is studied for immune modulation. Thymosin Beta-4/TB500 (43 amino acids/fragment) is studied for tissue repair and cell migration. They have completely different mechanisms and research applications.
It has the most extensive clinical evidence base of any immune peptide in the OSYRIS catalog, with data from clinical trials conducted in multiple countries over several decades.
Every Batch Tested by an Independent Lab
We publish the Certificate of Analysis for every product. See our full testing process.